

August 3, 2022

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir/Madam,

Sub: Intimation of Board Meeting.

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a Meeting of the Board of Directors of the Company will be held on **Thursday, August 11, 2022** to consider and approve inter alia, the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2022.

Further to our letter dated June 28, 2022 informing the closure of Trading Window of the Company from July 1, 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022, we inform you that the Trading Window will remain closed up to August 13, 2022 and shall be re-opened on August 14, 2022.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**



B. Adi Reddy
Company Secretary

